306 results about "Anaphylaxis treatment" patented technology

Devices, systems and methods are disclosed for treating bronchial constriction related to asthma, anaphylaxis or chronic obstructive pulmonary disease. The treatment comprises transmitting impulses of energy non-invasively to selected nerve fibers that are responsible for smooth muscle dilation. The transmitted energy impulses, comprising magnetic and / or electrical, mechanical and / or acoustic, and optical and / or thermal energy, stimulate the selected nerve fibers.

Devices, systems and methods for treating bronchial constriction related to asthma, anaphylaxis or chronic obstructive pulmonary disease wherein the treatment includes stimulating selected nerve fibers responsible for smooth muscle dilation at a selected region within a patient's neck, thereby reducing the magnitude of constriction of bronchial smooth muscle.

This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.

Devices, systems and instructing methods are disclosed for treating bronchial constriction related to asthma, anaphylaxis or chronic obstructive pulmonary disease. The instructing method for treatment comprises transmitting impulses of energy non-invasively to selected nerve fibers that are responsible for smooth muscle dilation. The transmitted energy impulses, comprising magnetic and / or electrical, mechanical and / or acoustic, and optical and / or thermal energy, stimulate the selected nerve fibers.

Devices, systems and methods are disclosed for treating bronchial constriction related to asthma, anaphylaxis, chronic obstructive pulmonary disease (COPD), exercise-induced bronchospasm and post-operative bronchospasm. The treatment comprises transmitting impulses of energy non-invasively to selected nerve fibers that activate neural pathways to reduce the release of acetycholine from airway-related vagal preganglionic neurons within the brain of the patient. The transmitted energy impulses, comprising magnetic and / or electrical energy, stimulate the selected nerve fibers to produce the bronchodilation.

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Devices, systems and methods are disclosed for treating bronchial constriction related to asthma, anaphylaxis or chronic obstructive pulmonary disease. The treatment comprises transmitting impulses of energy non-invasively to selected nerve fibers that are responsible for smooth muscle dilation. The transmitted energy impulses, comprising magnetic and / or electrical, mechanical and / or acoustic, and optical and / or thermal energy, stimulate the selected nerve fibers.

The invention relates to a method for preparing clindamycin phosphate powder filling agent, including: adding and dissolve clindamycin phosphate in alcohol solution; adding in activated charcoal to make decolorization, then roughly filtering, finely filtering, and placing to crystallize, filtering to eliminate supernatant and obtaining clindamycin phosphate crystal; then making transfer-solution for the second time, recrystallizing once, filtering and obtaining the recrystallized clindamycin phosphate crystal; drying and crushing, making split charging, capping and packaging in aseptic condition and making it. In the preparing course, it needs no high temperature treatment, need not add in additive, and its powder has good fluidity, high purity, few impurities, high bio-capability and good stability. It has no anaphylaxis and hemolysis and has no stimulation to blood vessels by intravenous injection. It adds a new clinic form of clindamycin phosphate, meeting clinic requirement.

Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL / sec to less than 1 mL / min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.

This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a methods of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.

The invention discloses a liquid bandage and a preparation method. The liquid bandage comprises the following raw materials: polyvinyl acetal, dibutyl phthalate, methyl cellulose, glycerol, laurocapram, chitosan, 95% ethanol, securidaca inappendiculata, dragon blood, frankincense, myrrh and sanchi; the preparation method comprises the following steps: stirring and dissolving the polyvinyl acetal,the chitosan and the ethanol at a temperature of 5 DEG C, and adding the laurocapram, the glycerol, the dibutyl phthalate and the methyl cellulose to obtain film liquid; performing reflux extraction on the crushed securidaca inappendiculata, dragon blood, frankincense, myrrh and sanchi with ethanol at a temperature of 60 DEG C until the extracted liquid is colorless, filtering at a normal pressure and concentrating; and adding the concentrated solution of the securidaca inappendiculata, the dragon blood, the frankincense, the myrrh and the sanchi into the film liquid and mixing uniformly. Theliquid bandage is convenient to use and has high water resistance and air permeability, without sticking on clothes and cotton-padded mattress, causing anaphylaxis and drug resistance or being limited by the shape, size and location of the wound.

One embodiment of the present invention relates to systems and methods for detecting harmful and / or hazardous ingredients that may cause an allergic reaction, interfere with the effectiveness of a prescription drug, exacerbate symptoms associated with a chronic illness, and / or cause another undesired reaction.

The present invention relates to methods of administering dosage forms which comprise epinephrine, including buccal, lingual, sublingual or transmucosal dosage forms comprising epinephrine for treatment of allergic emergencies, including anaphylaxis. Also provided herein are kits and packaging systems useful in these methods.

The present invention provides methods of treating IgE-associated disorders and compositions for use therein. The methods are particularly useful in treatment of allergies and allergy-related disorders. The methods generally comprise administering an IgE inhibitor (such as anti-IgE antibody) and an antigen and / or immunostimulatory polynucleotide sequence (ISS). These combination methods offer significant advantages, such as allowing more aggressive therapy while reducing unwanted side effects, such as anaphylaxis.

Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL / sec to less than 1 mL / min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.

This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.

The invention discloses a protecting and fixing device for wound, comprising at least one protecting and fixing layer with openings, wherein the protecting and fixing layer with openings is longitudinally provided with an opening for communicating the upper end face and the lower end face; the opening can enclose the wound therein so as to make the protecting and fixing layer with openings limit the wound tension and increase the mobile corrugation of the wounded skin. The invention can protect and fix the operation wound, the trauma wound or the catheter infusion wound into an opening which can limit the tension increase of the wound and the mobile corrugation of the surface skin of the wound and can prevent the wound from being torn and cracked and also avoid the damage for the wound due to the mobile corrugation and the surgical dressing of the wounded skin as well as the relative displacement frictions of the infusion catheter. Therefore, the invention fills the blank of current technology, which can enable the covered dressings to penetratively contact the secretion so as to absorb the exudate of the wound. Besides, the invention can prevent the foreign material contact anaphylaxis due to the wound contacting by compressing the dressing and the direct bonding of the catheter infusion wound and can prevent the re-injury of the wound caused by the synechia between the dressing and the wound secretion.

The invention relates to bread produced by rice flour and its making method, specific method of producing bread without glutens for anaphylaxis patient (Celiac Disease). Mainly selecting and mixing rice flour, pre-gelatinized starch, single glyceride, stearyl sodium lactate, refined granulated sugar, common salt, salad oil, shortening, water, and then mixing them continuously after adding yeast solution, adding hydroxyl-propyl-methyl-cellulose solution and making them into flour dough to get completed product after softening, baking and cooling. The invention is characterized on: good adaptability of manufacturing technique, easy and simple to handle, good product quality, not only provides good news to anaphylaxis patient, but also opens new channel to the comprehensive utilization and the lift of added value of rice flour; said product is without gluten, more and more applied on the foodstuff for anaphylaxis patient, and its external appearance, inner structure, taste is very near to those of traditional flour after subjective assessment.

The invention discloses a duplex dentin hypersensitivity resistant composition and an application of the composition. The active ingredients of the duplex dentin hypersensitivity resistant composition include a potassium salt and titanium containing bioactive glass, wherein the weight percentage of the potassium salt in the composition is 0.3-12%, and the weight percentage of the titanium containing bioactive glass in the composition is 0.5-15%. The duplex dentin hypersensitivity resistant composition disclosed by the invention can be used for preventing and treating (eliminating or relieving) dentin hypersensitivity; on one side, the potassium salt releases potassium ions to rapidly relieve pain (by reducing the excitability of a dental pulp nerve), on the other side, the bioactive glass can be used for supplementing minerals for a tooth structure to form stable carbonated hydroxyapatite so as to deeply close a dentinal tubule (by improving the permeability of the dentinal tubule); treatment effect is greatly improved, and aching feeling and anaphylaxis can be radically eliminated to achieve the purposes of treating both symptoms and root causes; in addition, as the bioactive glass comprises titanium, the phosphorite layer formed on the surface of a tooth is firmer and more wear-resistant, and the tooth can better resist daily stimulation.

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the topical application of immunoglobulin A coupled with J chain, and optionally coupled with secretory component in order to render the immunoglobulin A more physiologically active, for the prevention or treatment of ocular diseases including ocular immune deficiency and infections. Antigen-specific monoclonal immunoglobulin A may be used.

The present invention relates to novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel hetereocycles of the general formula (I). Also included is a method of treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.

The invention discloses a method for dyeing fabric by natural grape seed extract. The dyeing method comprises: pre-treating fabric blank by scouring enzyme; bleaching by hydrogen peroxide solution with concentration of 27%; preparing dyeing composition; heating the prepared dyeing composition; putting the fabric into the dyeing composition and dyeing; soaping the dyed fabric circularly by soda water; and dewatering and drying the soaped fabric. The method has good environment compatibility, biodegradability and medicament health caring property; can obtain the product with high chroma brilliant color or soft color, meanwhile avoids the serious pollution caused by chemical dye, and meet the requirement of environment protection; can obtain various brilliant high chroma colors and a large number of demitints by multiple dyeing of different times and different colors; and is nontoxic, harmless, has no anaphylaxis or carcinogenicity to skin. The invention can be widely used for producing high-grade real silk product, health caring underwear, hometextile product, and ornaments.

The invention discloses a waterborne polyurethane resin for a condom and a preparation method thereof. Concretely, the waterborne polyurethane resin with higher tensile strength and high rebound resilience is prepared through introducing a reactive sulfonate monomer into the polyurethane resin through a high-speed water-adding shear emulsifying method. The resin is higher in solid content and good in sag resistance, does not contain VOC (Volatile Organic Compounds) organic solvent and volatile organic amine, cannot cause anaphylaxis to a human body, and can be used for producing a safe and environment-friendly condom.

The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.

An application of the extract of pithecellobium clypearia benth / archidendron clypearia Jack. Nielsen in preparing food, cosmetics and medicines for treating allergic dermatitis, allergic rhinitis, allergic pharyngitis, pollen anaphylaxis and other allergic diseases is disclosed.